| scholarly article | Q13442814 |
| P2093 | author name string | Hong Shen | |
| P2860 | cites work | miRNA as markers for the diagnostic screening of colon cancer | Q38192078 |
| Microenvironment influence on human colon adenocarcinoma phenotypes and matrix metalloproteinase-2, p53 and β-catenin tumor expressions from identical monoclonal cell tumor in the orthotopic model in athymic nude rats | Q39044766 | ||
| Regulation of microRNA-1288 in colorectal cancer: altered expression and its clinicopathological significance. | Q39099530 | ||
| Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset | Q39117028 | ||
| Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. | Q40933980 | ||
| Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival | Q43722687 | ||
| Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases | Q43735744 | ||
| Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features | Q43760864 | ||
| Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? | Q44355201 | ||
| Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. | Q45057195 | ||
| Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. | Q45935444 | ||
| Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. | Q45938699 | ||
| Genetic polymorphism 609C>T in NAD(P)H:quinone oxidoreductase 1 enhances the risk of proximal colon cancer | Q46894038 | ||
| Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. | Q47988846 | ||
| Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability | Q51135450 | ||
| BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis | Q51369593 | ||
| Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma | Q54334205 | ||
| Distinguishing right from left colon by the pattern of gene expression | Q73806194 | ||
| Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer | Q77660297 | ||
| Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency | Q86600976 | ||
| Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment) | Q86668983 | ||
| Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations | Q87831057 | ||
| BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis | Q27852942 | ||
| Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | Q28262150 | ||
| Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age | Q30585819 | ||
| Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data | Q30780611 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Outcome of right- and left-sided colonic and rectal cancer following surgical resection | Q33622795 | ||
| Differences in telomerase activity between colon and rectal cancer | Q33671059 | ||
| KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). | Q33693309 | ||
| Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. | Q33727871 | ||
| Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer | Q33793501 | ||
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 | ||
| Right‐side and left‐side colon cancer follow different pathways to relapse | Q33924985 | ||
| Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer | Q33930691 | ||
| A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. | Q33945376 | ||
| Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147 | Q33947880 | ||
| Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial | Q34038277 | ||
| Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach | Q34052740 | ||
| Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution | Q34067781 | ||
| Risk factors associated with missed colorectal flat adenoma: a multicenter retrospective tandem colonoscopy study | Q34067926 | ||
| Podocalyxin is a marker of poor prognosis in colorectal cancer | Q34485223 | ||
| Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. | Q34553646 | ||
| Is there a difference in survival between right- versus left-sided colon cancers? | Q34594168 | ||
| Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy | Q34982575 | ||
| Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine | Q35067570 | ||
| Regression analysis of prognostic factors in colorectal cancer after curative resections | Q36451261 | ||
| Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers | Q36761405 | ||
| The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. | Q36896165 | ||
| BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. | Q37056074 | ||
| Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab | Q37067203 | ||
| Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon | Q37432567 | ||
| GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers | Q37534700 | ||
| Is microsatellite instability really a good prognostic factor of colorectal cancer? | Q37635680 | ||
| MicroRNAs 146a and 147b biomarkers for colorectal tumor's localization | Q37700483 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 6470-8 | |
| P577 | publication date | 2015-06-07 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Different treatment strategies and molecular features between right-sided and left-sided colon cancers | |
| P478 | volume | 21 |
| Q60912537 | CD44v6 engages in colorectal cancer progression |
| Q57213991 | Characteristics and Survival of Korean Patients With Colorectal Cancer Based on Data From the Korea Central Cancer Registry Data |
| Q37615044 | Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms. |
| Q94527907 | Clinicopathological differences and correlations between right and left colon cancer |
| Q88780422 | Colorectal Cancer: Why Does Side Matter? |
| Q48241834 | Colorectal cancer liver metastases - a population-based study on incidence, management and survival. |
| Q43640970 | Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection: Which side is better outcome? |
| Q47145867 | Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer |
| Q52724415 | D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer |
| Q61810809 | Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer |
| Q52586738 | Differences between carcinoma of the cecum and ascending colon: Evidence based on clinical and embryological data |
| Q90041896 | Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma |
| Q41367522 | Differences of protein expression profiles, KRAS and BRAF mutation, and prognosis in right-sided colon, left-sided colon and rectal cancer. |
| Q55430065 | Disparities in survival for right-sided vs. left-sided colon cancers in young patients: a study based on the Surveillance, Epidemiology, and End Results database (1990–2014). |
| Q64085481 | Does the Different Locations of Colon Cancer Affect the Oncologic Outcome? A Propensity-Score Matched Analysis |
| Q61810811 | Female Sex and Right-Sided Tumor Location Are Poor Prognostic Factors for Patients With Stage III Colon Cancer After a Curative Resection |
| Q47761632 | Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. |
| Q61451197 | Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel droplet-embedded drug sensitivity test |
| Q93018311 | Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria |
| Q55315465 | Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer. |
| Q47550821 | Is the Location of the Tumor Another Prognostic Factor for Patients With Colon Cancer? |
| Q47336855 | KRAS Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013. |
| Q64059336 | Long-term outcomes after surgical resection in patients with stage IV colorectal cancer: a retrospective study of 129 patients at a single institution |
| Q92382550 | Methylation of bone morphogenetic protein 2 is associated with poor prognosis in colorectal cancer |
| Q90216526 | Microarray‑based analysis of COL11A1 and TWIST1 as important differentially‑expressed pathogenic genes between left and right‑sided colon cancer |
| Q92125806 | Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis |
| Q37675952 | Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients |
| Q47163641 | Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer |
| Q92440787 | Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score |
| Q38847613 | Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. |
| Q33624491 | Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer |
| Q64927739 | Right- and left-sided stage III colon cancers present different prognostic outcomes of oxaliplatin-based adjuvant chemotherapy after curative resection. |
| Q95265907 | Screening and Identification of Differentially Expressed Genes Expressed among Left and Right Colon Adenocarcinoma |
| Q38722180 | Segmental distribution of some common molecular markers for colorectal cancer (CRC): influencing factors and potential implications |
| Q55497334 | Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer. |
| Q55396539 | Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. |
| Q93048468 | T Regulatory CD4+CD25+FoxP3+ Lymphocytes in the Peripheral Blood of Left-Sided Colorectal Cancer Patients |
| Q33591480 | TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma |
| Q54941578 | The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer. |
| Q41593315 | The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis |
| Q39238657 | The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. |
| Q90149581 | Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer |
| Q55313926 | Tumor location impact in stage II and III colon cancer: epidemiological and outcome evaluation. |
| Q92288452 | Tumor sidedness influences prognostic impact of lymph node metastasis in colon cancer patients undergoing curative surgery |
| Q91792262 | Tumor-suppressive function and mechanism of HOXB13 in right-sided colon cancer |
| Q38634544 | Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes |
| Q37644965 | Whether regional lymph nodes evaluation should be equally required for both right and left colon cancer |
Search more.